parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in late spermatids	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 8	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 11733

receipt 11742: NTN5 in dopamine neurons, braak

power: full sample -0.07 (p 0.781, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.07 (p 0.794, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.120, n 18). could be the mix.
skeptic: leave-one-out range -0.19 to +0.03, sign flips 4; without severely affected donors -0.07 (p 0.781, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NTN5 in dopamine neurons.

case closed: nothing better to follow up.

receipt 11741: NTN5 in astrocytes, braak

power: full sample -0.10 (p 0.689, n 18), 95% CI -0.54 to +0.38. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.15 (p 0.549, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.15 (p 0.561, n 18). could be the mix.
skeptic: leave-one-out range -0.26 to -0.02, sign flips 0; without severely affected donors -0.10 (p 0.689, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NTN5 in astrocytes.

case closed: nothing better to follow up.

loading the receipts